Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
What are the commercial prospects for treating eye disorders? Visiongain's report shows you potential revenues to 2022 - data, forecasts and discussions.
This study investigates prescription drugs treating human eye diseases. It lets you assess forecasted sales trends at world market, therapeutic submarket, product and national level to 2022.
How will 20 leading ophthalmic drugs - including Lucentis, Visudyne, Xalatan/Xalacom and Restasis - perform from 2012? Our investigation gives you business research and analysis with sales forecasts.
You also see forecasting of five submarkets to 2022, finding potential revenues:
• Glaucoma treatments
• Anti-allergy, anti-inflammatory and anti-infective agents
• Retinal disorder treatments
• Dry eye treatments
• Other medicines.
Find coverage of the R&D pipeline too, by therapeutic area, assessing trends and outlooks.
What will happen next? The pharma industry will improve treatment of ocular disorders and increase revenues there. The R&D pipeline in ophthalmology is strong. Also, improved drug delivery and new formulations will be important.
Visiongain predicts that the world market for ocular drugs will grow strongly from 2012 to 2022. It will be stimulated by increasing prevalence of eye disorders among aging populations. Some national treatment markets will grow fast; others will expand slowly.
What are leading companies doing? Our work discusses Allergan, Novartis, Pfizer, Roche and other pharmaceutical companies, evaluating prospects of the industry and market.
Sustained-release ocular implants, gene therapy and RNA interference technology will influence R&D, as will neuroprotective agents for glaucoma. Pipeline developments have strong potential. In 2012, under-met treatment needs remain.
What effects will competition have? New products - novel small molecules, generics and biologics - will change the sector. Many commercial opportunities for ophthalmic drugs exist, with high revenues possible to 2022. Our report shows and explains.
Revenue forecasts, market shares, developmental trends and discussions
In visiongain's report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP) and discussions of R&D activities. You receive 120 tables and charts and six research interviews.
Eight ways Ophthalmic Drugs: World Market Prospects 2012-2022 helps you
In particular, our study gives you the following knowledge on the topic:
• Find potential revenues to 2022 for the world market and submarkets
• Discover revenue forecasts to 2022 for 20 leading products
• See market forecasting to 2022 for US, Japan, EU5, Brazil, China and India
• Assess leading companies, discovering activities and outlooks
• Review R&D, seeing pipeline trends by therapeutic area
• Investigate competition and opportunities influencing sales
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, interviews with external authorities.
There, you find quantitative and qualitative analyses with independent predictions. You receive information that only our report contains.
American Academy of Ophthalmology (AAO) [US]
American Society of Retina Specialists (ASRS) [US]
Association for Research in Vision and Ophthalmology
Bausch & Lomb
Chugai Pharmaceutical Corp.
European Medicines Agency (EMEA/EMA)
Food and Drug Administration (FDA) [US]
Galderma International SA (Nestlé and L'Oréal)
Johnson & Johnson
Kyorin Pharmaceutical Co.
Kyowa Hakko Kirin Corp.
Merck & Co.
Ministry of Health, Labour and Welfare [Japan]
Moorfields Eye Hospital [UK]
National Eye Institute (NEI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institutes of Health (NIH) [US]
Otsuka Pharmaceutical Corp.
Oxford Eye Hospital [UK]
Rutgers University, Springfield, New Jersey [US]
Santen Pharmaceutical Corp.
Sanwa Kagaku Kenkyusho Corp.
Teva Pharmaceutical Industries
University College of London (UCL), Institute of Ophthalmology [UK]
University of Aston, Birmingham [UK]
University of Oxford [UK]